ParkinsonCanadaV1, Main, Exploration, bibRecord, 003547

α-Synuclein inclusions in Alzheimer and Lewy body diseases

Identifieur interne : 003547 ( Main/Exploration ); précédent : 003546; suivant : 003548

α-Synuclein inclusions in Alzheimer and Lewy body diseases

Auteurs : E. B. Mukaetova-Ladinska [États-Unis] ; J. Hurt [États-Unis] ; R. Jakes [États-Unis] ; J. Xuereb [États-Unis, Royaume-Uni] ; W. G. Honer [Canada] ; C. M. Wischik [Royaume-Uni]

Source :

Journal of neuropathology and experimental neurology [ 0022-3069 ] ; 2000.

RBID : Pascal:00-0275577

Descripteurs français

Pascal (Inist)
- Démence Alzheimer, Immunohistochimie, Protéine tau, Ubiquitine, Inclusion cellulaire, Diagnostic, Exploration, Personne âgée, α-Synucléine, Corps Lewy maladie.
Wicri :
- topic : Personne âgée.

English descriptors

KwdEn :
- Alzheimer disease, Cell inclusion, Diagnosis, Elderly, Exploration, Immunohistochemistry, Lewy body disease, Tau protein, Ubiquitin.

Abstract

α-Synuclein has assumed particular neuropathological interest in the light both of its identification as a non-β-amyloid plaque constituent in Alzheimer disease (AD), and the recent association between dominant inheritance of Parkinson disease (PD) and 2 missense mutations at positions 30 and 53 of the synuclein protein. We report a systematic study of α-synuclein, tau, and ubiquitin immunoreactivity in representative neurodegenerative disorders of late life. The α-synuclein association with Lewy bodies is variable, peripheral, and is not stable with respect to proteases or acid treatment, whereas there is no association with Pick bodies. Stable patterns of immunoreactivity included neurites and a novel inclusion body. Although there is an overlap between the presence of Lewy bodies and stable α-synuclein immunoreactivity, this is seen only in the presence of concomitant neuropathological features of AD. The novel α-synuclein inclusion body identified in pyramidal cells of the medial temporal lobe in particular was found in AD and in the Lewy body variant of AD, and was associated neither with ubiquitin nor tau protein. The inclusion is therefore neither a Lewy body nor a PHF-core body, but may be confused with the Lewy body, particularly in the Lewy body variant of AD. Abnormal processing of α-synuclein leading to its deposition in the form of proteolytically stable deposits is a particular feature of the intermediate stages of AD.

Affiliations:

Canada, Royaume-Uni, États-Unis

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000C98
to stream PascalFrancis, to step Curation: 000026
to stream PascalFrancis, to step Checkpoint: 000B42
to stream Main, to step Merge: 003A76
to stream Main, to step Curation: 003547

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">α-Synuclein inclusions in Alzheimer and Lewy body diseases</title>
<author><name sortKey="Mukaetova Ladinska, E B" sort="Mukaetova Ladinska, E B" uniqKey="Mukaetova Ladinska E" first="E. B." last="Mukaetova-Ladinska">E. B. Mukaetova-Ladinska</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cambridge Brain Bank Laboratory, MRC Centre, Hills Road</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Psychiatry, University of Cambridge Clinical School</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hurt, J" sort="Hurt, J" uniqKey="Hurt J" first="J." last="Hurt">J. Hurt</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cambridge Brain Bank Laboratory, MRC Centre, Hills Road</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Psychiatry, University of Cambridge Clinical School</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jakes, R" sort="Jakes, R" uniqKey="Jakes R" first="R." last="Jakes">R. Jakes</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Laboratory of Molecular Biology, MRC Centre, Hills Road</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Xuereb, J" sort="Xuereb, J" uniqKey="Xuereb J" first="J." last="Xuereb">J. Xuereb</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cambridge Brain Bank Laboratory, MRC Centre, Hills Road</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology, University of Cambridge Clinical School</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Honer, W G" sort="Honer, W G" uniqKey="Honer W" first="W. G." last="Honer">W. G. Honer</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Psychiatry, University of British Columbia</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wischik, C M" sort="Wischik, C M" uniqKey="Wischik C" first="C. M." last="Wischik">C. M. Wischik</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Mental Health, University of Aberdeen</s1>
<s2>Aberdeen</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Aberdeen</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0275577</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0275577 INIST</idno>
<idno type="RBID">Pascal:00-0275577</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C98</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000026</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000B42</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000B42</idno>
<idno type="wicri:doubleKey">0022-3069:2000:Mukaetova Ladinska E:synuclein:inclusions:in</idno>
<idno type="wicri:Area/Main/Merge">003A76</idno>
<idno type="wicri:Area/Main/Curation">003547</idno>
<idno type="wicri:Area/Main/Exploration">003547</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">α-Synuclein inclusions in Alzheimer and Lewy body diseases</title>
<author><name sortKey="Mukaetova Ladinska, E B" sort="Mukaetova Ladinska, E B" uniqKey="Mukaetova Ladinska E" first="E. B." last="Mukaetova-Ladinska">E. B. Mukaetova-Ladinska</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cambridge Brain Bank Laboratory, MRC Centre, Hills Road</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Psychiatry, University of Cambridge Clinical School</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hurt, J" sort="Hurt, J" uniqKey="Hurt J" first="J." last="Hurt">J. Hurt</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cambridge Brain Bank Laboratory, MRC Centre, Hills Road</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Psychiatry, University of Cambridge Clinical School</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jakes, R" sort="Jakes, R" uniqKey="Jakes R" first="R." last="Jakes">R. Jakes</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Laboratory of Molecular Biology, MRC Centre, Hills Road</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Xuereb, J" sort="Xuereb, J" uniqKey="Xuereb J" first="J." last="Xuereb">J. Xuereb</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cambridge Brain Bank Laboratory, MRC Centre, Hills Road</s1>
<s2>Cambridge</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology, University of Cambridge Clinical School</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Honer, W G" sort="Honer, W G" uniqKey="Honer W" first="W. G." last="Honer">W. G. Honer</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Psychiatry, University of British Columbia</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wischik, C M" sort="Wischik, C M" uniqKey="Wischik C" first="C. M." last="Wischik">C. M. Wischik</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Mental Health, University of Aberdeen</s1>
<s2>Aberdeen</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Aberdeen</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of neuropathology and experimental neurology</title>
<title level="j" type="abbreviated">J. neuropathol. exp. neurol.</title>
<idno type="ISSN">0022-3069</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of neuropathology and experimental neurology</title>
<title level="j" type="abbreviated">J. neuropathol. exp. neurol.</title>
<idno type="ISSN">0022-3069</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer disease</term>
<term>Cell inclusion</term>
<term>Diagnosis</term>
<term>Elderly</term>
<term>Exploration</term>
<term>Immunohistochemistry</term>
<term>Lewy body disease</term>
<term>Tau protein</term>
<term>Ubiquitin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Démence Alzheimer</term>
<term>Immunohistochimie</term>
<term>Protéine tau</term>
<term>Ubiquitine</term>
<term>Inclusion cellulaire</term>
<term>Diagnostic</term>
<term>Exploration</term>
<term>Personne âgée</term>
<term>α-Synucléine</term>
<term>Corps Lewy maladie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Personne âgée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">α-Synuclein has assumed particular neuropathological interest in the light both of its identification as a non-β-amyloid plaque constituent in Alzheimer disease (AD), and the recent association between dominant inheritance of Parkinson disease (PD) and 2 missense mutations at positions 30 and 53 of the synuclein protein. We report a systematic study of α-synuclein, tau, and ubiquitin immunoreactivity in representative neurodegenerative disorders of late life. The α-synuclein association with Lewy bodies is variable, peripheral, and is not stable with respect to proteases or acid treatment, whereas there is no association with Pick bodies. Stable patterns of immunoreactivity included neurites and a novel inclusion body. Although there is an overlap between the presence of Lewy bodies and stable α-synuclein immunoreactivity, this is seen only in the presence of concomitant neuropathological features of AD. The novel α-synuclein inclusion body identified in pyramidal cells of the medial temporal lobe in particular was found in AD and in the Lewy body variant of AD, and was associated neither with ubiquitin nor tau protein. The inclusion is therefore neither a Lewy body nor a PHF-core body, but may be confused with the Lewy body, particularly in the Lewy body variant of AD. Abnormal processing of α-synuclein leading to its deposition in the form of proteolytically stable deposits is a particular feature of the intermediate stages of AD.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Mukaetova Ladinska, E B" sort="Mukaetova Ladinska, E B" uniqKey="Mukaetova Ladinska E" first="E. B." last="Mukaetova-Ladinska">E. B. Mukaetova-Ladinska</name>
</noRegion>
<name sortKey="Hurt, J" sort="Hurt, J" uniqKey="Hurt J" first="J." last="Hurt">J. Hurt</name>
<name sortKey="Hurt, J" sort="Hurt, J" uniqKey="Hurt J" first="J." last="Hurt">J. Hurt</name>
<name sortKey="Jakes, R" sort="Jakes, R" uniqKey="Jakes R" first="R." last="Jakes">R. Jakes</name>
<name sortKey="Mukaetova Ladinska, E B" sort="Mukaetova Ladinska, E B" uniqKey="Mukaetova Ladinska E" first="E. B." last="Mukaetova-Ladinska">E. B. Mukaetova-Ladinska</name>
<name sortKey="Xuereb, J" sort="Xuereb, J" uniqKey="Xuereb J" first="J." last="Xuereb">J. Xuereb</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Xuereb, J" sort="Xuereb, J" uniqKey="Xuereb J" first="J." last="Xuereb">J. Xuereb</name>
</noRegion>
<name sortKey="Wischik, C M" sort="Wischik, C M" uniqKey="Wischik C" first="C. M." last="Wischik">C. M. Wischik</name>
</country>
<country name="Canada"><noRegion><name sortKey="Honer, W G" sort="Honer, W G" uniqKey="Honer W" first="W. G." last="Honer">W. G. Honer</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003547 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003547 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:00-0275577
   |texte=   α-Synuclein inclusions in Alzheimer and Lewy body diseases
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

α-Synuclein inclusions in Alzheimer and Lewy body diseases

α-Synuclein inclusions in Alzheimer and Lewy body diseases

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri